Kropotova Alexandra has recently acquired 38,000 stock options in iBio, Inc., a significant move that may enhance her role within the company. This acquisition, reported in a recent SEC filing, underscores the ongoing efforts to incentivize key personnel in the pharmaceutical preparations sector.
Background
Kropotova Alexandra is a reporting owner associated with iBio, Inc., which operates in the pharmaceutical preparations industry. The company is publicly traded under the ticker symbol IBIO and is listed on the relevant exchanges. iBio, Inc. focuses on advancing biotechnology solutions and has undergone name changes in the past, including its former names iBioPharma, Inc. and InB:Biotechnologies, Inc.
What the Filing Says
The filing, dated October 15, 2026, indicates that Kropotova acquired the stock options at an exercise price of $0.78 per share. The options are set to vest pro rata in monthly installments over twelve months, contingent on her continued service with the company. Following this transaction, Kropotova will own a total of 38,000 shares directly.
Impact
This acquisition may impact the company by strengthening Kropotova's financial stake and involvement in iBio, Inc. As a director, her increased ownership could align her interests with those of other shareholders, potentially driving strategic initiatives within the firm.
What's Next
The filing does not say what happens next.